{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062074","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.286126+00:00","generated_at":"2026-06-08T06:37:06.078059+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M","bullets":["Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.","Cash and securities $149.1M as of Sept 30, 2023; combined with offering proceeds, cash runway into H2 2026.","Q3 2023 net loss $18.5M vs $15.9M YoY; R&D expenses $15.4M (up from $11.3M) driven by Phase 2/3 trial costs.","Positive Phase 2 data for bel-sar in choroidal melanoma: 80% tumor control, 90% visual acuity preservation at 12 months.","FDA agreed under SPA for Phase 3 CoMpass trial design; first patient dosing expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062074","json":"https://secwatch.observer/filing/0000950170-23-062074.json","markdown":"https://secwatch.observer/filing/0000950170-23-062074.md","text":"https://secwatch.observer/filing/0000950170-23-062074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/aura-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:37:06.078059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b2f3137a3a1ad9d6b8eb53323153d6d38cdf4d4","claim":"Aura Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, the Company issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a7488843ed955638c45049b3eb7d2ce5f56adc84","claim":"Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein valued at approximately $92.6 million (effective 2023-11-06).","evidence_excerpt":"On November 6, 2023, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), to the Underwriters at a public offering price of $9.00 per share (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $92.6 million"},{"label":"Effective","value":"2023-11-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}